Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of acenocoumarol pharmacodynamics.

Clinical pharmacology and therapeutics - 1 May 2004

Morin Sandrine, Bodin Laurent, Loriot Marie-Anne, Thijssen Henk H W, Robert Annie, Strabach Soraya, Verstuyft Céline, Tregouet David-Alexandre, Dubert Liliane, Laurent-Puig Pierre, Funck-Brentano Christian, Jaillon Patrice, Beaune Philippe H, Becquemont Laurent

Abstract excerpt

OBJECTIVE: The aim of this study was to investigate the respective contribution of the different cytochrome P450 (CYP) 2C9 genetic polymorphisms to the interindividual variability of acenocoumarol pharmacodynamic response. METHODS: A total of 263 healthy volunteers were genotyped for CYP2C9*2, CYP2C9*3, CYP2C9*4, and CYP2C9*5 alleles, as well as for the nicotinamide adenine dinucleotide phosphate, reduced,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acenocoumarol
Share to Administration, Oral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anticoagulants

Share to Area Under Curve

Share to Cytochrome P-450 CYP2C9

Share to Factor VII

Share to International Normalized Ratio

Share to NAD(P)H Dehydrogenase (Quinone)

Source

Identifiers

PMID: 15116053
DOI: 10.1016/j.clpt.2004.01.008

Genes

NQO1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of acenocoumarol pharmacodynamics.PMID 15116053Read ↗

Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.Semantic proximity Read ↗

Cytochrome P450 2C9 polymorphism and acenocoumarol therapy.Semantic proximity Read ↗

Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype.Semantic proximity Read ↗

Genetic contribution of CYP2C9, CYP2C19, and APOE variants in acenocoumarol response.Semantic proximity Read ↗

Pharmacogenetics aspects of oral anticoagulants therapy.Semantic proximity Read ↗

[Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].Semantic proximity Read ↗

[Pharmacogenetics and interindividual variability in drug response: cytochrome P-450 2C9 and coumarin anticoagulants].Semantic proximity Read ↗

VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients.Semantic proximity Read ↗

Effect of different genetics variants: CYP2C9*2, CYP2C9*3 of cytochrome P-450 CYP2C9 and 1639G>A of the VKORC1 gene; On acenocoumarol requirement in Moroccan patients.Semantic proximity Read ↗

Acenocoumarol sensitivity and pharmacokinetic characterization of CYP2C9 *5/*8,*8/*11,*9/*11 and VKORC1*2 in black African healthy Beninese subjects.Semantic proximity Read ↗

Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment.Semantic proximity Read ↗

CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment: implication for clinical practice in Hungary.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.